Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single‐Center Retrospective Analysis

Documenti analoghi

• Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia
  di: Michael K. Jones, et al.
  Pubblicazione: (2026)
• Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study
  di: Cassandre Petit, et al.
  Pubblicazione: (2025)
• Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia
  di: Somedeb Ball, et al.
  Pubblicazione: (2026)
• Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
  di: Tapan M. Kadia, et al.
  Pubblicazione: (2026)
• Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML ‐ M4 and AML ‐ M5 , Treated With Venetoclax Plus Azacitidine
  di: Marina Konopleva, et al.
  Pubblicazione: (2026)